Company Filing History:

20 out of 43

Vernalis Research Limited

patents

2 out of 4,945

Hoffmann-la Roche Inc.

patents

where one patent can have more than one assignee

Years Active: 2002-2008

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7323487 - Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands (2008-01-29),

2. 7323486 - Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands (2008-01-29),

3. 7323473 - [object Object] (2008-01-29),

4. 7173056 - Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands (2007-02-06),

5. 7166632 - Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands (2007-01-23),

6. 7166613 - [object Object] (2007-01-23),

7. 7145009 - Pirazino(aza)indole derivatives (2006-12-05),

8. 7098337 - 1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives (2006-08-29),

9. 7022707 - Piperazine derivatives (2006-04-04),

10. 6962939 - [object Object] (2005-11-08),

11. 6831078 - Azetidinecarboxamide derivatives for treating CNS disorders (2004-12-14),

12. 6800627 - Pirazino indole derivatives (2004-10-05),

13. 6706750 - Indole derivatives process for their preparation, pharmaceutical compositions containing them and their medicinal application (2004-03-16),

14. 6608085 - 4-quinolinemethanol derivatives as purine receptor antagonists (II) (2003-08-19),

15. 6552062 - Indazole derivatives with 5-HT2 receptor activity (2003-04-22),

Title: The Innovative Journey of David Reginald Adams

Introduction:

David Reginald Adams, a visionary inventor from Wokingham, GB, has left an indelible mark on the technological landscape with his groundbreaking inventions. With a total of 20 patents to his name, Adams is a trailblazer in the world of innovation, particularly in the realm of chemical compounds and pharmaceutical applications.

Latest Patents:

Among his latest patents are revolutionary chemical compounds with the potential to be used as agonists or antagonists of 5HT receptors, particularly in the treatment of various disorders of the central nervous system, cardiovascular issues, gastrointestinal ailments, and even obesity. These condensed indoline derivatives showcase Adams' relentless pursuit of advancements in therapeutic applications.

Career Highlights:

Having worked with esteemed companies such as Vernalis Research Limited and Hoffmann-La Roche Inc., Adams has honed his expertise in the field of pharmaceutical research and development. Through his innovative approach and commitment to excellence, Adams has consistently pushed the boundaries of traditional pharmaceutical practices, paving the way for novel treatment options.

Collaborations:

Throughout his career, Adams has collaborated closely with notable professionals in the field, including Jonathan Richard Anthony Roffey and Howard Langham Mansell. These fruitful collaborations have further fueled Adams' inventive spirit, leading to the creation of groundbreaking solutions with far-reaching implications in the realm of healthcare and pharmaceuticals.

Conclusion:

In conclusion, David Reginald Adams emerges as a frontrunner in the realm of innovation, with a profound impact on the advancement of pharmaceutical science. His relentless pursuit of novel solutions and his collaborative efforts underscore his dedication to pushing the boundaries of what is possible in the world of technology and healthcare. Adams' legacy as a pioneering inventor continues to inspire future generations of innovators to think boldly and dream big in their pursuit of transformative discoveries.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com